Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Partners With Reference Lab to Develop Multi-Analyte Assays

NEW YORK, Feb. 13 - Beckman Coulter and Specialty Laboratories have signed a cross-licensing agreement to develop multi-analyte assays for the Beckman Progressive microarray platform, the instrument manufacturer said on Wednesday.

 

Under the deal, Specialty Laboratories will have early access to Beckman Coulter's assay-development technology. Beckman will in turn have access to multi-analyte assays that Specialty may develop as a result.

 

Financial details of the arrangement were not disclosed.

 

The companies expect that testing services resulting from the collaboration may be available by the end of the year.

 

The Beckman technology will allow Specialty Laboratories to produce multiple analytical results from one sample incubation, Specialty Laboratories Chairman and CEO James Peter said in a statement.

 

Specialty Laboratories, based in Santa Monica, Calif., is a clinical reference laboratory that serves hospitals, labs, and physicians. The company also  conducts R&D independently and in conjunction with biotech firms.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.